Catalent adds potent drug capabilities in Schorndorf, Germany facility

This important new capability enables Catalent to provide customers with complex and innovative dose form production, overencapsulation, and packaging solutions for potent products at its Schorndorf site.

For nearly 50 years, Catalent's Schorndorf operation has provided a broad range of services to global, regional and local pharmaceutical customers. Today, Catalent provides oral dose form development, manufacturing and packaging services, as well as comprehensive supply chain solutions. In the fall of 2009, Catalent's Schorndorf facility successfully completed an FDA inspection adding to a long track record of regulatory compliance, including German and other EU and international regulatory authorities.

“We believe the addition of this new potent handling and over-encapsulation area will help to meet the needs of our customers, both global and local. I am also pleased that this investment was made here in Schorndorf, as it builds upon our team's commitment to operational excellence, our regulatory track record, and our consistent focus on meeting our customers' needs,” said Eric Schmidhaeuser, Managing Director of the Schorndorf operation.